Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effect of a single administration of a DPP-IV
inhibitor (vildagliptin: Galvus ®) versus no treatment over two populations of diabetic
patients: without diabetic autonomic neuropathy (NA, i.e. the control group) and with
diabetic autonomic neuropathy (i.e. the neuropathy group). The investigators hypothesize that
the therapeutic efficacy of DPP-IV inhibitors is partly mediated by the autonomic nervous
system. This hypothesis will be validated if a lower glycemic response to DPP-IV inhibitor
treatment is observed for the neuropathy group compared to control.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Toulouse
Collaborators:
Faculty of Medicine, Toulouse Institute of Molecular Medicine of Rangueil (I2MR) Novartis Pharmaceuticals